Glaxosmithkline Intellectual Property Development Limited

Smithkline Beecham Corporation

Glaxosmithkline LLC

University of North Carolina at Chapel Hill

Viiv Healthcare Company

Jun Tang

Vincent Wing-Fai Tai

Jerry Leroy Adams

Jeffrey Michael Axten

David Margolis

Toshihiro Hamajima

Richard M Dunham

James Francis Callahan

Brian Alvin Johns

Kenneth Allen Newlander

Dashyant Dhanak

Michael Tolar Martin

Martha Alicia De La Rosa

Domingos J Silva

Hideyuki Sato

Dirk Andries Heerding

Joelle Lorraine Burgess

Shinichiro Matsunaga

Stuart Paul Romeril

Nicholas D Adams

Deborah Lynne Bryan

Cynthia A Parrish

Subba Reddy Katamreddy

Nianhe Han

Jing Fang

Seth Wilson Grant

Martha A Sarpong

Andrew J Carpenter

Christopher R Conlee

Gregory Peckham

Masaichi Hasegawa

Yasushi Miyazaki

Yanhong Feng

Amita M Chaudhari

Marcus Semones

Kien S Du

Satoru Ida

Jesus Raul Medina

Yutaka Maeda

David Favre

Jesus Rual Medina

Jean-Philippe Rocher

Masato Nakano

Ichiro Mori

Robert G Ferris

Mark Andrew Hatcher

Elie Amine Tabet

Brian Andrew Chauder

The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

Compounds useful in HIV therapy

The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

The invention relates to compounds of Formula (I), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.

The invention relates a compound of the formula: a pharmaceutically acceptable salt thereof, compositions thereof, and methods of therapeutic treatment using the same.

The invention relates to compounds of Formula (I), (II), (III) or (IV), salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects.

Ingenol analogs, pharmaceutical compositions and methods of use thereof

The present invention relates to a compound characterized by the following Formula I: 

Propenoate derivatives of betulin

The invention is directed to substituted indoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R, and Rare defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, ocular diseases, and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, Type 1 diabetes Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis, myocardial infarction, cardiovascular disease, atherosclerosis, and arrhythmias, and more specifically cancers of the breast, colon, pancreatic, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Chemical compounds

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

Bicyclic compounds and use as antidiabetics

This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.

The present invention relates to anilinopyrazole derivatives, methods for the preparation of such anilinopyrazoles, and use of such anilinopyrazoles in the treatment of certain diseases or conditions. In particular, the present invention relates to a nilinopyrazole derivatives useful as CDK2 inhibitors and use of the anilinopyrazoles in the treatment of disorders mediated by inappropriate CDK2 activity.

Substituted anilinopyrazoles

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Azaindole inhibitors of aurora kinases

3-carboxy quinoline derivatives, which are useful as YAK3 inhibitors are described herein. The described invention also includes methods of making such 3-carboxy quinoline derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate YAK3 activity.

Furo- and thienopyrimidine derivatives, which are useful as TIE-2 and/or VEGFR-2 inhibitors are described herein. The described invention also includes methods of making such furo- and thienopyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof

Growing community of inventors

Research Triangle Park, NC, United States of America

Jun Tang